Menopause Formula Gets Third Clinical Trial

October 20, 2014

The supplier of EstroG-100 says no other ingredients in today's market bear a comparable Phase II and Phase III clinical trial with similar protocols.

EstroG-100 is already a popular menopausal formula, now manufactured into finished health products by the likes of NOW Foods, Doctor’s Best, and Swanson Health Products. Results of a third clinical study, though, could really open the market for this herbal mix.

For 12 week, 70 women in various menopausal states (pre, peri, and post) were assigned to an EstroG-100 dietary supplement or placebo. Based on participant responses to questionnaires, EstroG-100 significantly reduced a large number of menopausal symptoms, including insomnia, vertigo, joint and muscle pain, hot flashes, and vaginal dryness. The results back previous trials of three months and an entire year of supplementing with EstroG-100.

“As far as we know, there are no menopause ingredients in the nutra market today that bear a comparable Phase II trial and Phase III human clinical trial study with similar protocols,” said Michael Jeffers of EstroG-100 supplier Helios Corp. (Santa Fe, NM), who added that study participants have seen significant health improvements in as little as one week.

EstroG-100 is an herbal combination of Angelica gigas root extract (pictured above), Cynanchum wilfordii root extract, and Phlomis umbrosa root extract. The formula is non-estrogenic and is backed by New Dietary Ingredient (NDI) status.

 

Photo by Wikimedia Commons contributor Hardyplants.

Related Content:

Women's Health